The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell ResolutionOrit Rozenblatt–Rosen, Kristen Anton, Aviv Regev et al.|Cell|2020Cited by 602
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Zhiao Shi et al.|Cancer Discovery|2022Cited by 139
Microscaled proteogenomic methods for precision oncologyShankha Satpathy, Matthew J. Ellis, Eric J. Jaehnig et al.|Nature Communications|2020Cited by 122
MITI minimum information guidelines for highly multiplexed tissue imagesDenis Schapiro, Alyce A. Chen, Clarence Yapp et al.|Nature Methods|2022Cited by 86
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74